このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Cambridge Nutritional Sciences マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

James Cooper

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	1.1yrs

経営陣の近況

Recent updates

The Market Doesn't Like What It Sees From Cambridge Nutritional Sciences plc's (LON:CNSL) Revenues Yet

Jul 27

Cambridge Nutritional Sciences plc's (LON:CNSL) Shares Lagging The Industry But So Is The Business

Mar 14

We Think Omega Diagnostics Group (LON:ODX) Needs To Drive Business Growth Carefully

Nov 06

This Is Why Omega Diagnostics Group PLC's (LON:ODX) CEO Compensation Looks Appropriate

Sep 09

Companies Like Omega Diagnostics Group (LON:ODX) Are In A Position To Invest In Growth

Jun 14

How Does Omega Diagnostics Group's (LON:ODX) CEO Salary Compare to Peers?

Mar 01

Announcing: Omega Diagnostics Group (LON:ODX) Stock Soared An Exciting 301% In The Last Year

Feb 01

What You Need To Know About Omega Diagnostics Group PLC's (LON:ODX) Investor Composition

Jan 04

We're Hopeful That Omega Diagnostics Group (LON:ODX) Will Use Its Cash Wisely

Dec 09

CEO（最高経営責任者

James Cooper (33 yo)

less than a year

在職期間

Mr. James Cooper had been Chief Operating Officer of Cambridge Nutritional Sciences plc since May 24, 2024 until 2024 and is its Executive Director since May 24, 2024 and has been its Interim CEO since Aug...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
James Cooper	Interim CEO & Executive Director	less than a year	データなし	データなし
Iain Alexander Logan	Group Financial Controller	13.8yrs	データなし	データなし
Prashant Maniar	Managing Director of Omega Dx Asia Pvt Limited	12.9yrs	データなし	データなし
Charlene Roderman	Company Secretary	less than a year	データなし	データなし
Andrew Shepherd	Global Ambassador - Life President	no data	UK£317.15k	データなし

6.8yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: CNSLの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
James Cooper	Interim CEO & Executive Director	less than a year	データなし	データなし
Jeremy Millard	Independent Non-Executive Director	5.5yrs	UK£37.00k	0.43% £ 37.9k
Carolyn Rand	Independent Non-Executive Chair	1.1yrs	UK£113.00k	データなし

1.1yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: CNSLの取締役会は経験豊富ではない ( 1.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Cambridge Nutritional Sciences マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Cambridge Nutritional Sciences plc, Annual General Meeting, Sep 26, 2024

Cambridge Nutritional Sciences plc Announces Chief Executive Officer Changes

Cambridge Nutritional Sciences plc Appoints James Cooper to the Board as Chief Operating Officer and Executive Director

Cambridge Nutritional Sciences plc Announces Board Changes

Cambridge Nutritional Sciences plc Announces Appointment of James Cooper as Operations Director

Chris Lea to Leave Omega Diagnostics Group plc as Group Finance Director

Recent updates

Cambridge Nutritional Sciences plc, Annual General Meeting, Sep 26, 2024

Cambridge Nutritional Sciences plc Announces Chief Executive Officer Changes

The Market Doesn't Like What It Sees From Cambridge Nutritional Sciences plc's (LON:CNSL) Revenues Yet

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Cambridge Nutritional Sciences plc to Report Fiscal Year 2024 Results on Jul 25, 2024

New minor risk - Financial data availability

Cambridge Nutritional Sciences plc Appoints James Cooper to the Board as Chief Operating Officer and Executive Director

Cambridge Nutritional Sciences plc Announces Board Changes

Cambridge Nutritional Sciences plc's (LON:CNSL) Shares Lagging The Industry But So Is The Business

Cambridge Nutritional Sciences plc Announces Appointment of James Cooper as Operations Director

Cambridge Nutritional Sciences plc Provides Revenue Guidance for the Fiscal Year 2024

First half 2024 earnings released: UK£0.003 loss per share (vs UK£0.004 loss in 1H 2023)

New minor risk - Share price stability

Cambridge Nutritional Sciences plc to Report First Half, 2024 Results on Nov 23, 2023

Chris Lea to Leave Omega Diagnostics Group plc as Group Finance Director

Omega Diagnostics Group plc Appoints Carolyn Rand as an Independent Non-Executive Director

Omega Diagnostics Group PLC, Annual General Meeting, Sep 06, 2023

New major risk - Revenue and earnings growth

Full year 2023 earnings released: UK£0.014 loss per share (vs UK£0.008 loss in FY 2022)

Omega Diagnostics Group PLC to Report Fiscal Year 2023 Results on Aug 03, 2023

Consensus forecasts updated

Price target decreased to UK£0.12

Omega Diagnostics Group PLC to Report First Half, 2023 Results on Nov 24, 2022

Omega Reports for the VISITECT® CD4 Advanced Disease Rapid Test, Issued by the World Health Organisation

Full year 2022 earnings: EPS misses analyst expectations

Omega Diagnostics Group PLC LONDON Common Shares Deleted from OTC Equity

Accubio Limited completed the acquisition of CD4 Business of Omega Diagnostics Group PLC (AIM:ODX) for GBP 5.1 million.

Omega Diagnostics Group PLC, Annual General Meeting, Oct 05, 2022

An unknown buyer signed Heads of Terms to acquire CD4 Business of Omega Diagnostics Group PLC (AIM:ODX).

Price target decreased to UK£0.18

Omega Diagnostics Group plc Provides Revenue Guidance for the Full Year Ended 31 March 2022

Accubio Limited signed a conditional sale and purchase agreement to acquire Diagnostic Test kit Manufacturing Business and Facility in Alva, Scotland from Omega Diagnostics Group PLC (AIM:ODX) for £1 million.

Omega Diagnostics Group PLC, Annual General Meeting, Mar 07, 2022

First half 2022 earnings: EPS and revenues miss analyst expectations

We Think Omega Diagnostics Group (LON:ODX) Needs To Drive Business Growth Carefully

This Is Why Omega Diagnostics Group PLC's (LON:ODX) CEO Compensation Looks Appropriate

Omega Announces VISITECT COVID-19 Antigen Self-Test Submission Update

Group Finance Director, Company Secretary & Executive Director Kieron Harbinson has left the company

Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.049 loss in FY 2020)

Omega Diagnostics Group plc Announces FDA Submission for Emergency Use Authorization

Companies Like Omega Diagnostics Group (LON:ODX) Are In A Position To Invest In Growth

Omega Diagnostics Gp Provides Regulatory Progress for Visitect® Covid-19 Test

Omega Diagnostics Group plc Announces Positive Data for Covid-19 Antigen Test

Omega Diagnostics Group PLC Announces Positive Data for Mologic COVID-19 Antigen Test

Independent Non-Executive Director exercised options and sold UK£192k worth of stock

Omega Diagnostics Group plc Announces Contract with the Development of Health and Social Care to Provide Manufacturing Capacity for Covid-19 Lateral Flow Antigen Test

Omega Signs Contract with Screen4 Ltd

How Does Omega Diagnostics Group's (LON:ODX) CEO Salary Compare to Peers?

Omega Diagnostics Group plc UK-RTC Statement on Abc-19Tm Rapid Antibody Test

Omega Diagnostics Group plc Announces Abc-19 Rapid Antibody Test Performance Data

Group Finance Director exercised options and sold UK£582k worth of stock

Omega Announces Changes to Its Board

Omega Agrees Contract with the Department of Health and Social Care

New 90-day high: UK£0.92

Announcing: Omega Diagnostics Group (LON:ODX) Stock Soared An Exciting 301% In The Last Year

Omega Diagnostics Group plc Announces the Launch of Covid-19 Antibody Laboratory-Based Testing Service

What You Need To Know About Omega Diagnostics Group PLC's (LON:ODX) Investor Composition

We're Hopeful That Omega Diagnostics Group (LON:ODX) Will Use Its Cash Wisely

First half 2021 earnings released: UK£0.002 loss per share

New 90-day low: UK£0.48

Omega Diagnostics Group PLC Announces Chinese Approval for Food Detective® Test

Omega Diagnostics Group PLC to Report First Half, 2021 Results on Nov 30, 2020

Omega Diagnostics Group plc Announces First Order for One Million COVID-19 Lateral Flow Antibody Tests

New 90-day high: UK£0.94

New 90-day high - UK£0.65

Omega Diagnostics Group PLC to Report Fiscal Year 2020 Results on Jul 14, 2020

Omega Diagnostics Group PLC has completed a Follow-on Equity Offering in the amount of £3.01244 million.

CEO（最高経営責任者

在職期間

マネジメント基準チェック /14